Infertility

... JAMA - Sign In Page Select Journal or Resource JAMA & Archives Home JAMA Archives of Dermatology Facial Plastic Surgery Family Medicine (1992-2000) General Psychiatry Internal Medicine Neurology Ophthalmology Otolaryngology—Head & Neck Surgery Pediatrics & Adolescent Medicine Surgery Student JAMA (1998-2004) JAMA & Archives CME Calendar of Events JAMA CareerNet For The Media Users’ Guides to the Medical Literature Peer Review Congress This item is restricted.

Subscribers have full text access and guests have some free access.

SIGN IN or see below for access options.

Full Text Shyness, Social Anxiety, and Impaired Self-esteem in Turner Syndrome and Premature...

Schmidt et al.JAMA.2006; 295: 1374-1376.

Sign In User Name Purchase Article - Y...

... JAMA - Sign In Page Select Journal or Resource JAMA & Archives Home JAMA Archives of Dermatology Facial Plastic Surgery Family Medicine (1992-2000) General Psychiatry Internal Medicine Neurology Ophthalmology Otolaryngology—Head & Neck Surgery Pediatrics & Adolescent Medicine Surgery Student JAMA (1998-2004) JAMA & Archives CME Calendar of Events JAMA CareerNet For The Media Users’ Guides to the Medical Literature Peer Review Congress This item is restricted.

Subscribers have full text access and guests have some free access.

SIGN IN or see below for access options.

Full Text Challenging the Strategy of Maternal Age–Based Prenatal Genetic Counseling Berkowitz et al.JAMA.2006; 295: 1446-1448.

Sign In User Name Purchase Article - You m...

... PharmaLive: Genaera Appoints Michael J.

Gast, MD, PhD to Lead Clinical Research and Development TODAY ON PHARMALIVE.COM Genaera Appoints Michael J.

Gast, MD, PhD to Lead Clinical Research and Development PLYMOUTH MEETING, Pa., March 21, 2006 /PRNewswire-FirstCall/ - Genaera Corporation today announced the appointment of Michael J.

Gast, MD, PhD, as Senior Vice President, Clinical Research and Development.

Dr.

Gast served as Chief Medical Officer of Genaera during the first half of 2005 and left briefly to pursue personal interests.

He has been a full-time consultant to the Company since November of 2005.

"We are very pleased to have Mike return to the Genaera management team," said Jack Armstrong, President and CEO of Genaera Corporation.

"Mike's guidance has been invaluable as we have adapted and refined our clinical strategy for EVIZON(TM) (squalamine lactate) over the past year.

In his new role he will provide strong leadership and essential expertise for the next development phase of this product and all of our programs moving forward.

His appointment is part of my commitment to expanding our management and advisory resources in areas critical to our success." "This is an exciting time for Genaera, and I'm pleased to be rejoining this talented and committed team," said Dr.

Gast.

"I'm very enthusiastic about the clinical potential of each of the drug candidates in our broad development portfolio, particularly EVIZON, which I believe represents a unique and highly diffe...